A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

308

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Non-Hodgkin Lymphoma

Interventions

DRUG: BMS-986458
DRUG: Rituximab
DRUG: Glofitamab/Obinutuzumab
DRUG: Mosunetuzumab

Sponsor

Bristol-Myers Squibb